Debevoise & Plimpton LLP is advising Access Industries in its investment in the $5.6 billion acquisition of the equity of Calpine, America’s largest generator of electricity from natural gas and geothermal resources. Read more >

Debevoise & Plimpton LLP is advising Discovery Communications, Inc. on its acquisition of Scripps Networks Interactive, Inc. The transaction is valued at $14.6 billion and is expected to close in early 2018. Read more >

The London office of Debevoise & Plimpton LLP has represented longstanding client NLMK, a global steel producer, in its successful defence in the English High Court against an application to enforce a Russian arbitral award that had been set aside by the Russian courts. Read more >

Debevoise & Plimpton LLP is advising Clayton, Dubilier & Rice, a private investment firm, on the $2.5 billion acquisition of HD Supply’s Waterworks Division, the largest distributor of waterworks products in the U.S. Debevoise is also advising on the financing aspects of the transaction. Read more >

Debevoise & Plimpton LLP and the Center for Reproductive Rights filed a new lawsuit against the state of Louisiana’s abortion clinic licensing law that has forced most of the clinics in the state to close. Read more >

Debevoise & Plimpton LLP is advising Tribune Media Company (NYSE: TRCO) on its $3.9 billion sale to Sinclair Broadcast Group, Inc. (Nasdaq: SBGI) in a transaction valued at nearly $6.6 billion. The transaction has been unanimously approved by the Boards of Directors of both companies and is anticipated to close in the fourth quarter of 2017. Read more >

Debevoise & Plimpton LLP is advising CF Corporation and The Blackstone Group, one of the world's leading investment firms, on the $1.835 billion all-cash acquisition of Fidelity & Guaranty Life. The transaction is expected to close in the fourth quarter of 2017. Read more >

Debevoise & Plimpton LLP has advised Global Infrastructure Partners (GIP), a leading independent global infrastructure investor, in connection with the formation of its latest fund, Global Infrastructure Partners III. The fund successfully closed with $15.8 billion in capital commitments, making it the largest infrastructure fund and one of the largest private investment fund programs ever raised. Read more >

Debevoise & Plimpton LLP is advising Verizon on its acquisition of Straight Path Communications, a leading wireless spectrum holder, in a $3.1 billion all-stock transaction. The transaction has been approved by the boards of directors of both Straight Path and Verizon and is expected to close within nine months. Read more >

The London and Frankfurt offices of Debevoise & Plimpton LLP have advised Helios Investment Partners (“Helios”) in the formation of a joint-venture with GBfoods, creating one of Africa's largest FMCG groups, operating in 30 African countries, including leadership positions in Nigeria and Ghana. Read more >

The Moscow and London offices of Debevoise & Plimpton LLP have advised longstanding client PJSC “MMC “Norilsk Nickel” (“Nornickel”) in its $1 billion Eurobond offering due 2023 with a coupon of 4.10% per annum. Read more >

The London office of Debevoise & Plimpton LLP has advised the Center for Reproductive Rights on a pro bono basis as it secured strong, ground-breaking recommendations from the United Nations Committee on the Elimination of Discrimination Against Women in Geneva (“CEDAW Committee”) to overturn El Salvador’s total criminalization of abortion. Read more >

Debevoise & Plimpton LLP has advised Clayton, Dubilier & Rice in connection with the formation of its latest fund, Clayton, Dubilier & Rice Fund X. The fund successfully closed with total capital commitments of $10 billion. CD&R’s Fund X generated strong support from both existing investors, with more than 90% of Fund IX LPs re-committing to Fund X, and a select group of new strategic relationships that resulted in a diverse mix of nearly 200 LPs globally. Read more >

Debevoise & Plimpton LLP is advising Sawai Pharmaceutical Co. Ltd., a leading Japanese generic pharmaceuticals manufacturer, in its $1.05 billion acquisition of the generic pharmaceuticals business of Upsher-Smith Laboratories, Inc. The transaction is expected to close near the end of June 2017. Read more >